LeMaitre Vascular ROA 2007-2019 | LMAT
Current and historical return on assets (ROA) values for LeMaitre Vascular (LMAT) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. LeMaitre Vascular ROA for the three months ending June 30, 2019 was 11.15%.
| LeMaitre Vascular ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2019-06-30 | $0.02B | $0.16B | 12.26% |
| 2019-03-31 | $0.02B | $0.16B | 15.49% |
| 2018-12-31 | $0.02B | $0.15B | 16.34% |
| 2018-09-30 | $0.02B | $0.14B | 15.67% |
| 2018-06-30 | $0.02B | $0.14B | 17.15% |
| 2018-03-31 | $0.02B | $0.13B | 14.75% |
| 2017-12-31 | $0.02B | $0.13B | 14.59% |
| 2017-09-30 | $0.02B | $0.12B | 14.48% |
| 2017-06-30 | $0.01B | $0.11B | 13.27% |
| 2017-03-31 | $0.01B | $0.11B | 11.82% |
| 2016-12-31 | $0.01B | $0.10B | 11.22% |
| 2016-09-30 | $0.01B | $0.10B | 11.55% |
| 2016-06-30 | $0.01B | $0.10B | 10.90% |
| 2016-03-31 | $0.01B | $0.09B | 10.17% |
| 2015-12-31 | $0.01B | $0.09B | 9.38% |
| 2015-09-30 | $0.01B | $0.09B | 8.46% |
| 2015-06-30 | $0.01B | $0.08B | 7.32% |
| 2015-03-31 | $0.01B | $0.08B | 6.13% |
| 2014-12-31 | $0.00B | $0.08B | 5.08% |
| 2014-09-30 | $0.00B | $0.08B | 3.95% |
| 2014-06-30 | $0.00B | $0.08B | 4.18% |
| 2014-03-31 | $0.00B | $0.07B | 4.44% |
| 2013-12-31 | $0.00B | $0.07B | 6.06% |
| 2013-09-30 | $0.00B | $0.07B | 6.23% |
| 2013-06-30 | $0.00B | $0.06B | 6.37% |
| 2013-03-31 | $0.00B | $0.06B | 6.48% |
| 2012-12-31 | $0.00B | $0.06B | 4.94% |
| 2012-09-30 | $0.00B | $0.06B | 3.33% |
| 2012-06-30 | $0.00B | $0.06B | 3.31% |
| 2012-03-31 | $0.00B | $0.06B | 3.28% |
| 2011-12-31 | $0.00B | $0.06B | 3.25% |
| 2011-09-30 | $0.00B | $0.06B | 6.43% |
| 2011-06-30 | $0.01B | $0.06B | 8.10% |
| 2011-03-31 | $0.01B | $0.06B | 9.88% |
| 2010-12-31 | $0.01B | $0.06B | 11.72% |
| 2010-09-30 | $0.01B | $0.06B | 10.30% |
| 2010-06-30 | $0.01B | $0.06B | 8.77% |
| 2010-03-31 | $0.00B | $0.06B | 7.14% |
| 2009-12-31 | $0.00B | $0.06B | 1.83% |
| 2009-09-30 | $0.00B | $0.06B | 0.00% |
| 2009-06-30 | $-0.00B | $0.05B | -1.88% |
| 2009-03-31 | $-0.00B | $0.05B | -5.58% |
| 2008-12-31 | $-0.00B | $0.05B | -7.24% |
| 2008-09-30 | $-0.01B | $0.05B | -8.77% |
| 2008-06-30 | $-0.01B | $0.06B | -10.39% |
| 2008-03-31 | $-0.01B | $0.06B | -8.66% |
| 2007-12-31 | $-0.00B | $0.06B | -5.22% |
| 2007-06-30 | $-0.00B | $0.06B | -4.73% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.626B | $0.106B |
| LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $149.840B | 28.17 |
| Medtronic (MDT) | Ireland | $137.817B | 19.69 |
| Stryker (SYK) | United States | $81.180B | 28.07 |
| Boston Scientific (BSX) | United States | $58.714B | 28.48 |
| Baxter (BAX) | United States | $44.403B | 26.93 |
| EssilorLuxottica Societe Anonyme (ESLOY) | France | $30.829B | 0.00 |
| Zimmer Biomet Holdings (ZBH) | United States | $28.130B | 18.00 |
| Coloplast (CLPBY) | Denmark | $26.395B | 42.14 |
| Lonza Group Ag (LZAGY) | Switzerland | $26.038B | 0.00 |
| Terumo (TRUMY) | Japan | $23.788B | 27.35 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $20.267B | 0.00 |
| ResMed (RMD) | United States | $19.315B | 36.83 |
| Sunny Optical Technology (SNPTF) | China | $13.689B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.759B | 52.32 |
| Canopy Growth (CGC) | Canada | $9.745B | 0.00 |
| Insulet (PODD) | United States | $9.055B | 536.57 |
| William Demant Holdings (WILYY) | Denmark | $7.136B | 0.00 |
| Haemonetics (HAE) | United States | $7.033B | 53.07 |
| Hill-Rom Holdings (HRC) | United States | $7.032B | 20.97 |
| Perrigo (PRGO) | Ireland | $6.283B | 11.57 |
| Aurora Cannabis (ACB) | Canada | $6.094B | 59.90 |
| GN STORE NORD (GNNDY) | Denmark | $5.897B | 30.11 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $4.651B | 0.00 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $4.296B | 0.00 |
| Neogen (NEOG) | United States | $3.710B | 61.70 |
| ICU Medical (ICUI) | United States | $3.430B | 22.25 |
| NuVasive (NUVA) | United States | $3.316B | 26.44 |
| Hutchison China MediTech (HCM) | China | $2.737B | 0.00 |
| Quidel (QDEL) | United States | $2.552B | 25.34 |
| Agios Pharmaceuticals (AGIO) | United States | $2.491B | 0.00 |
| National Vision Holdings (EYE) | United States | $2.177B | 46.98 |
| Cardiovascular Systems (CSII) | United States | $1.682B | 0.00 |
| Aphria (APHA) | $1.551B | 0.00 | |
| Phibro Animal Health (PAHC) | United States | $1.263B | 18.92 |
| AtriCure (ATRC) | United States | $1.060B | 0.00 |
| VAREX IMAGING (VREX) | United States | $1.018B | 23.45 |
| NanoString Technologies (NSTG) | United States | $0.977B | 0.00 |
| Omeros (OMER) | United States | $0.967B | 0.00 |
| PetIQ (PETQ) | United States | $0.908B | 21.44 |
| Lantheus Holdings (LNTH) | United States | $0.897B | 23.57 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.794B | 20.23 |
| Cerus (CERS) | United States | $0.769B | 0.00 |
| MacroGenics (MGNX) | United States | $0.737B | 0.00 |
| Quanterix (QTRX) | United States | $0.702B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.648B | 0.00 |
| Surmodics (SRDX) | United States | $0.601B | 114.26 |
| OraSure Technologies (OSUR) | United States | $0.446B | 20.63 |
| Meridian Bioscience (VIVO) | United States | $0.432B | 13.48 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.423B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.376B | 123.63 |
| United Health Products (UEEC) | United States | $0.350B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.349B | 25.56 |
| Zynex (ZYXI) | United States | $0.345B | 36.62 |
| Owens & Minor (OMI) | United States | $0.306B | 9.17 |
| Bovie Medical (APYX) | United States | $0.251B | 0.00 |
| Vapotherm (VAPO) | United States | $0.244B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.155B | 0.00 |
| Chimerix (CMRX) | United States | $0.153B | 0.00 |
| Fonar (FONR) | United States | $0.152B | 8.01 |
| Rockwell Medical (RMTI) | United States | $0.152B | 0.00 |
| Female Health (VERU) | United States | $0.123B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.099B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.097B | 0.00 |
| United-Guardian (UG) | United States | $0.087B | 20.65 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.057B | 0.00 |
| Surface Oncology (SURF) | United States | $0.055B | 0.00 |
| Nephros (NEPH) | United States | $0.054B | 0.00 |
| MRI INTERVENTNS (MRIC) | United States | $0.048B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.041B | 14.17 |
| Senestech (SNES) | United States | $0.039B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.013B | 0.00 |
| Myomo (MYO) | United States | $0.011B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.011B | 0.00 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.010B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.006B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.005B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.003B | 0.00 |
